- Report
- March 2024
- 118 Pages
Global
From €4343EUR$4,500USD£3,726GBP
- Report
- January 2024
- 200 Pages
Global
From €4006EUR$4,150USD£3,436GBP
- Report
- February 2021
- 360 Pages
United States
From €2316EUR$2,400USD£1,987GBP
- Report
- February 2019
- 105 Pages
Global
From €1245EUR$1,290USD£1,068GBP
- Drug Pipelines
- June 2019
- 579 Pages
Global
€21234EUR$22,000USD£18,215GBP
- Report
- January 2019
- 717 Pages
Global
From €21234EUR$22,000USD£18,215GBP
- Drug Pipelines
- January 2022
- 30 Pages
Global
From €483EUR$500USD£414GBP
- Report
- January 2019
- 35 Pages
Global
From €965EUR$1,000USD£828GBP
- Report
- June 2019
- 14 Pages
Global
€9652EUR$10,000USD£8,279GBP
- Report
- June 2019
- 26 Pages
Global
€9652EUR$10,000USD£8,279GBP
- Report
- February 2024
- 87 Pages
Global
From €3500EUR$3,884USD£3,107GBP
- Report
- November 2023
- 35 Pages
Global
From €5617EUR$5,820USD£4,819GBP
Isentress is a brand name for the antiretroviral drug raltegravir, which is used to treat HIV/AIDS. It is a type of integrase inhibitor, which works by blocking the action of the HIV enzyme integrase, preventing the virus from replicating. Isentress is usually prescribed in combination with other antiretroviral drugs, and is available in tablet and oral suspension forms. It is generally well-tolerated, with few side effects.
Isentress is marketed by Merck & Co., Inc., and is available in many countries around the world. Other companies that market raltegravir include Mylan Pharmaceuticals, Teva Pharmaceuticals, and ViiV Healthcare. Show Less Read more
